Gosset Ownership
Private
Employees
~30
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Samsara Therapeutics General Information
Samsara Therapeutics develops small molecule drugs that activate autophagy to treat age-related neurodegenerative diseases. Their most advanced programs are in preclinical development targeting ALS, CMT Type Ia, and Parkinson's disease. The company uses a proprietary phenotypic screening platform based on patient-derived iPSCs to discover novel compounds that restore or enhance cellular autophagy. No clinical results have been reported yet as all lead candidates remain preclinical.
Contact Information
Primary Industry
Biotech
Corporate Office
Oxford, Oxfordshire
United Kingdom
United Kingdom
Drug Pipeline
SAM001
INDKey Partnerships
Apollo Health Ventures led Series A funding round, additional support from patient advocacy organizations.
Samsara Therapeutics Funding
No funding data available
To view Samsara Therapeutics's complete valuation and funding history, request access »